COSCO SHIP PORT (01199) reported that profit attributable to shareholders for the first three quarters rose 19.7% year on year to US$316 million.
COSCO SHIPPING Ports (01199) announced that for the three months ended September 30, 2026, total throughput rose 8.4% year on year to 42.2666 million TEU; equity throughput rose 8.1% year on year to 12.8846 million TEU; the company's revenue rose 13.0% year on year to US$484 million; profit attributable to equity holders of the company rose 0.1% year on year to US$82.589 million; basic earnings per share were 2.06 US cents.
COSCO SHIP PORT (01199) announced that for the 3 months ended September 30, 2026, total throughput rose 8.4% year on year to 42.2666 million TEU; equity throughput rose 8.1% year on year to 12.8846 million TEU; the company's revenue rose 13.0% year on year to US$484 million; profit attributable to equity holders of the company rose 0.1% year on year to US$82.589 million; basic earnings per share were 2.06 US cents.
For the 9 months ended September 30, 2026, total throughput rose 8.1% year on year to 122 million TEU; equity throughput rose 7.4% year on year to 37.3766 million TEU; the company's revenue rose 12.6% year on year to US$1.39 billion; profit attributable to equity holders of the company rose 19.7% year on year to US$316 million; basic earnings per share were 7.95 US cents.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process

Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process

Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%






